MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance
- 1 October 2019
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 157 (4) , 1153-1155.e1
Abstract
No abstract availableFunding Information
- Dutch Cancer Society
This publication has 11 references indexed in Scilit:
- Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapyNature Reviews Cancer, 2018
- MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 IsoformsGastroenterology, 2017
- Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal CancerClinical Cancer Research, 2017
- Gastrointestinal malignancies harbor actionable MET exon 14 deletionsOncotarget, 2015
- Sequential cancer mutations in cultured human intestinal stem cellsNature, 2015
- MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR InhibitorsCancer Research, 2014
- Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's EpitheliumGastroenterology, 2011
- Wnt activity defines colon cancer stem cells and is regulated by the microenvironmentNature Cell Biology, 2010
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Expression of c-Met and Heparan-Sulfate Proteoglycan Forms of CD44 in Colorectal CancerThe American Journal of Pathology, 2000